SITC 2021 Virtual PlatformBoth in-person and virtual participants of the 36th Annual Meeting & Pre-Conference Programs (SITC 2021) can now access the SITC 2021 virtual website. Log in using the email address used to register and your confirmation number.
Now AvailableRegular and YIA Abstract Titles and Authors With a record-breaking number of abstract submissions, SITC is excited to announce titles and authors for regular and Young Investigator Award (YIA) abstracts and posters that will be presented at the upcoming 36th Annual Meeting.
Download the new SITC Clinical Practice Guidelines (CPG) Mobile App! The first and only immunotherapy-specific clinical practice guidelines app featuring guideline content and expert panel recommendations in an easy-to-navigate format. The app includes interactive tools, bookmarks, and advanced search capabilities.Available for FREE for iOS and Android.
Cancer Immunotherapy Winter School, Jan. 24–28, 2022
SITC is pleased to host its fourth annual and first hybrid Cancer Immunotherapy Winter School, a comprehensive cancer immunotherapy education program, Jan. 24–28, 2022.
New SITC Clinical Practice Guidelines Published
JITC Increases Impact Factor to 13.751The Journal for ImmunoTherapy of Cancer's (JITC) Impact Factor makes JITC the highest ranked fully open access immunology journal and places it in the top 5% percent of all journals published in the category of immunology and top 7% in the category of oncology.
A series of eight two-hour online seminars will feature experts in a given subject area to provide an overview of the current scientific knowledge about an area of immunotherapy. An interactive Q&A session will follow the topic overview, providing attendees the opportunity to ask in-depth questions of the faculty as well as offering a forum for networking and initiation of collaborations with others working in a similar field.
Comprised of several authoritative reviews of COVID-19 and Cancer Immunotherapy, this series, edited by Paolo Antonio Ascierto, MD and Jason D. Goldman, MD, MPH, will explore basic insights into the immunology of the novel coronavirus, repurposing of immune-based therapies including the effects of immune-oncology agents, and the affected cancer populations.
Join Alan Hutson, PhD, and the thousands of other cancer immunotherapy professionals who proudly call themselves SITC members.
Explore resources and educational opportunities for cancer patients and those who advocate for them.
Track the latest advancements and educational opportunities in tumor immunology and cancer immunotherapy.
Advance science, submit your manuscript and monitor the global progress of cancer immunotherapy research.
Hosted by Arthur and Sandra Irving, this working symposium will focus on advancing the careers of young scientists doing research in cancer immunology. ~15 accomplished faculty mentors will share their research career experience in cancer immunology with ...
Hi Todd, I just saw your message. If you can get a chapter to me by December 15th, this would work. My email is firstname.lastname@example.org Thanks, Priya ------------------------------ Priya Hays PhD Senior Technical Writer Personalis San Mateo CA -- ...
SITC community, I would like to announce the release of my book Advancing Healthcare Through Personalized Medicine, Second Edition by Springer Nature. The book has an in-depth discussion of precision oncology and cancer immunotherapies, among other topics ...
Donate today to support early career scientists who are emerging leaders seeking to advance research in the cancer immunotherapy field.
An open access, peer-reviewed journal, the Journal for ImmunoTherapy of Cancer (JITC) is the global voice of the society, producing original research articles, literature reviews and more on tumor immunology and cancer immunotherapy.
It is the mission of the Society for Immunotherapy of Cancer (SITC) to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com